A PROPENSITY SCORE-BASED COMPARISON OF TEPOTINIB VERSUS IMMUNOTHERAPY WITH/WITHOUT CHEMOTHERAPY, USING REAL-WORLD DATA IN PREVIOUSLY UNTREATED MET EXON 14 (METEX14) SKIPPING NON-SMALL CELL LUNG CANCER (NSCLC)

被引：0
|
作者：
Hook, E. [1 ]
Batteson, R. [2 ]
Christopoulos, P. [3 ,4 ,5 ]
Guisier, F. [6 ,7 ]
Ekman, S. [8 ]
Hatswell, A.
Vioix, H. [9 ]
机构：
[1] Delta Hat Ltd, Nottingham, NGM, England
[2] Delta Hat Ltd, Nottingham, England
[3] Heidelberg Univ Hosp, Thoraxklin, Heidelberg, Germany
[4] Heidelberg Univ Hosp, Natl Ctr Tumor Dis, Heidelberg, Germany
[5] German Ctr Lung Res DZL, Translat Lung Res Ctr Heidelberg TLRC H, Heidelberg, Germany
[6] Univ Rouen Normandie, Dept Pneumol, LITIS Lab QuantIF team EA4108, CHU Rouen, F-76000 Rouen, France
[7] Inserm CIC CRB 1404, F-76000 Rouen, France
[8] Karolinska Univ Hospital, Dept Oncol Pathol, Karolinska Inst, Stockholm, Sweden
[9] Merck Healthcare KGaA, Darmstadt, Germany
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
CO168
引用
收藏
页码：S44 / S44
页数：1
相关论文
共 50 条
  • [21] US real-world (RW) patient characteristics with METex14 skipping advanced non-small cell lung cancer (aNSCLC)
    Kelly, R. J.
    Le, X.
    Luttropp, K.
    Yang, M.
    Liu, F.
    Huse, S.
    Ganz, M. L.
    Pfeiffer, B.
    Paik, P. K.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1088 - S1089
  • [22] ctDNA analysis in the savolitinib phase II study in Non-Small Cell Lung Cancer (NSCLC) patients (pts) harboring MET exon 14 skipping alterations (METex14).
    Yu, Yongfeng
    Ren, Yongxin
    Fang, Jian
    Cao, Lejie
    Liang, Zongan
    Guo, Qisen
    Han, Sen
    Ji, Zimei
    Wang, Ye
    Sun, Yulan
    Chen, Yuan
    Li, Xingya
    Xu, Hua
    Zhou, Jianying
    Jiang, Liyan
    Cheng, Ying
    Han, Zhigang
    Shi, Jianhua
    Chen, Gongyan
    Ma, Rui
    Fan, Yun
    Sun, Sanyuan
    Jiao, Longxian
    Jia, Xiaoyun
    Wang, Linfang
    Lu, Puhan
    Li, Jing
    Xu, Qian
    Luo, Xian
    Su, Weiguo
    Lu, Shun
    CANCER RESEARCH, 2021, 81 (13)
  • [23] Mechanisms of acquired resistance to MET tyrosine kinase inhibitors (TKIs) in MET exon 14 (METex14) mutant non-small cell lung cancer (NSCLC).
    Awad, Mark M.
    Bahcall, Magda
    Sholl, Lynette M.
    Wilson, Frederick Hugh
    Paweletz, Cloud
    Capelletti, Marzia
    Leonardi, Giulia Costanza
    Watanabe, Masayuki
    Baba, Hideo
    Chambers, Emily S.
    Redig, Amanda J.
    Nishino, Mizuki
    VanderLaan, Paul A.
    Costa, Daniel Botelho
    Imamura, Yu
    Janne, Pasi A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [24] TOGETHER: Pooled real-world datasets of METex14 skipping NSCLC and adjusted comparison of upfront (chemo-) immunotherapy with tepotinib from VISION
    Christopoulos, P.
    Ekman, S.
    Guisier, F.
    Ho, C.
    Blasi, M.
    Brunnstrom, H.
    Cvetkovic, J.
    Kazdal, D.
    Kuon, J. B.
    de Flon, F. Haglund
    Stenzinger, A.
    Wong, S.
    Hatswell, A.
    McLean, T.
    Bergman, S.
    Orlowski, K.
    Grupp, A. M. OBrate
    Vioix, H.
    Thomas, M.
    ANNALS OF ONCOLOGY, 2023, 34
  • [25] Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation
    Brazel, Danielle
    Zhang, Shannon
    Nagasaka, Misako
    LUNG CANCER-TARGETS AND THERAPY, 2022, 13 : 33 - 45
  • [26] Clinical and genomic analysis of non-small cell lung cancer (NSCLC) patients with MET exon14 skipping (METex14) mutations and responses to anti-MET therapy.
    McKenzie, Andrew
    Fisher, Arielle
    Correll, Mick
    Jones, Carissa
    Correia, Jessica
    Thurber, James
    Misch, Amanda
    Heritage, Jessica
    Sturgill, Emma
    Jones, Suzanne Fields
    Johnson, Melissa Lynne
    Spigel, David R.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [27] TEPOTINIB COMPARED WITH CHEMOIMMUNOTHERAPY IN FIRST-LINE NON-SMALL CELL LUNG CANCER (NSCLC): MATCHING ADJUSTED INDIRECT COMPARISON (MAIC) OF VISION IN MET EXON 14 (METEX14) SKIPPING NSCLC AND KEYNOTE-189 IN WILD-TYPE NSCLC
    Vioix, H.
    Hatswell, A.
    McLean, T.
    Day, C.
    Batteson, R.
    Hook, E.
    Alexopoulos, S.
    Baijal, S.
    VALUE IN HEALTH, 2022, 25 (12) : S36 - S36
  • [28] COST-EFFECTIVENESS OF TEPOTINIB FOR PATIENTS WITH PREVIOUSLY TREATED ADVANCED NON-SMALL CELL LUNG CANCER HARBORING METEX14 SKIPPING ALTERATIONS IN SPAIN
    Arriola, E.
    Batteson, R.
    Hook, E.
    Wheat, H.
    Vioix, H.
    Morros, M.
    Aguila, M.
    de los Santos Real, H.
    Soberon S, Fernandez
    Brines, M.
    Vazquez, S.
    VALUE IN HEALTH, 2023, 26 (06) : S86 - S86
  • [29] Modelling the Effectiveness of Tepotinib in Comparison to Standard-of-Care Treatments in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Harbouring METex14 Skipping in the UK
    Batteson, Rachael
    Hook, Emma
    Wheat, Hollie
    Hatswell, Anthony J.
    Vioix, Helene
    Mclean, Thomas
    Alexopoulos, Stamatia Theodora
    Baijal, Shobhit
    Paik, Paul K.
    TARGETED ONCOLOGY, 2024, 19 (02) : 191 - 201
  • [30] Modelling the Effectiveness of Tepotinib in Comparison to Standard-of-Care Treatments in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Harbouring METex14 Skipping in the UK
    Rachael Batteson
    Emma Hook
    Hollie Wheat
    Anthony J. Hatswell
    Helene Vioix
    Thomas McLean
    Stamatia Theodora Alexopoulos
    Shobhit Baijal
    Paul K. Paik
    Targeted Oncology, 2024, 19 : 191 - 201
12345